Skip to main content

Table 3 Clinicopathologic characteristics of seven patients positive for RET rearrangements

From: A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

Study Age (years) Sex Race Smoking status* Histology EGFRstatus KRASstatus Dose/day Exposure RECIST response Tumor shrinkage Reason for discontinuation RET partner % cells with rearrangements detected
Vandetanib
ZODIAC 68 F Asian Non-smoker Adenocarcinoma Mutation negative Negative 100 mg 21 days Progressive disease Progressive disease KIF5B 50%
ZEPHYR 69 F White Non-smoker Adenocarcinoma Mutation negative; amplification positive Negative 300 mg 180 days Stable disease 23% shrinkage of target lesions Adverse event KIF5B 75–100%
ZEPHYR 59 F Asian Non-smoker Adenocarcinoma Mutation negative; amplification positive Negative 300 mg 57 days Progressive disease 33% shrinkage of target lesions (progressive disease in non-target lesions) Progressive disease KIF5B 50–75%
Comparator
ZODIAC 59 F White Ex-smoker Adenocarcinoma Mutation negative Unknown Six cycles docetaxel Partial response (day 85); progressive disease (day 210) 32% shrinkage of target lesions at day 85 Completed six cycles KIF5B 75–100%
ZEAL** 58 M White Ex-smoker Large cell carcinoma Mutation negative Negative Five cycles pemetrexed Progressive disease (day 245) None Completed five cycles Not known 75–100%
ZEPHYR 57 M White Ex-smoker Adenocarcinoma Mutation negative Negative 26 days placebo Progressive disease (day 25) None Progressive disease KIF5B 75–100%
ZEST** 70 M White Ex-smoker Adenocarcinoma Mutation negative; amplification positive Negative 315 days erlotinib Progressive disease (day 166) None Progressive disease Not known 25–50%
  1. F, female; M, male. *Non-smoker = never smoked >20 g tobacco in lifetime; ex-smoker = stopped smoking ≥1 year ago; occasional smoker = <1 tobacco product per day; habitual smoker = ≥1 tobacco product per day. **RET rearrangements with unknown, non-KIF5B fusion partners.